Anixa Biosciences (NASDAQ:ANIX – Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02, Zacks reports.
Anixa Biosciences Price Performance
ANIX opened at $2.25 on Friday. Anixa Biosciences has a 52 week low of $2.14 and a 52 week high of $5.13. The business has a fifty day simple moving average of $2.94 and a 200-day simple moving average of $3.02. The firm has a market cap of $72.40 million, a P/E ratio of -5.77 and a beta of 0.90.
Wall Street Analyst Weigh In
Several research firms have issued reports on ANIX. HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Anixa Biosciences in a research note on Tuesday, November 19th. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a report on Tuesday, November 19th.
Anixa Biosciences Company Profile
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Featured Stories
- Five stocks we like better than Anixa Biosciences
- Stock Market Sectors: What Are They and How Many Are There?
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- Why Are Stock Sectors Important to Successful Investing?
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- Upcoming IPO Stock Lockup Period, Explained
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
